FocusCANCER PHARMACOLOGY

Eco-evolution of cancer resistance

See allHide authors and affiliations

Science Translational Medicine  24 Feb 2016:
Vol. 8, Issue 327, pp. 327fs5
DOI: 10.1126/scitranslmed.aaf3802

eLetters is an online forum for ongoing peer review. Submission of eLetters are open to all. Please read our Terms of Service before submitting your own eLetter.

Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • Plain text
    No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests
CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

No eLetters have been published for this article.

View Full Text

Article Tools

  • Email
  • Download Powerpoint
  • Print

  • Alerts
  • Citation tools

  • Eco-evolution of cancer resistance

    By Giannoula L. Klement

    Science Translational Medicine : 327fs5

    Contrary to high-dose cytotoxic chemotherapy, where they proliferate unopposed, drug-resistant cancer cells may be at an evolutionary disadvantage in presence of low-dose chemotherapy owing to the high metabolic cost of their resistance mechanisms (Enriquez-Navas et al., this issue).

    CiteULike logo Connotea logo del.icio.us logo Digg logo Facebook logo Google logo Mendeley logo Reddit logo Twitter logo

My saved folders

Stay Connected to Science Translational Medicine

Related Content

Similar Articles in:

Citing Articles in: